LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
VOR
Vor Biopharma Inc.
There isn't enough reported data to score VOR yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
VOR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
VOR's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
VOR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.3x | $19.30 | -0.1% |
| Fair | 0.3x | $19.67 | +1.8% |
| Current | 0.3x | $19.32 | — |
| Expensive | 0.4x | $19.68 | +1.9% |
Historical ranges are pointers, not guarantees.
VOR has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
VOR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect VOR's earnings to decline, with its revenue and profitability holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over VOR on earnings, with more consistent year-over-year improvement.
VOR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $56.23 | +$443.06 |
| Q2 2026 | -$63.95 | +$209.25 |
| Q1 2026 | -$313.99 | -$283.79 |
| Q4 2025 | -$314.08 | -$280.08 |
| Q3 2025 | -$386.83 | -$354.03 |
| Q2 2025 | -$273.20 | -$238.60 |
| Q1 2025 | -$30.20 | +$5.20 |
| Q4 2024 | -$34.00 | +$1.00 |
VOR has returned to profit: it earned $56.23 per share over the past year, after losing money the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
VOR Quarterly Revenue
VOR and LLY do not have enough comparable growth data to identify a winner.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over VOR on cash generation, producing positive trailing cash flow while its opponent burns cash.
VOR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$32.8M | +$21.1M |
| Q2 2026 | -$25.5M | +$9.8M |
| Q1 2026 | -$38.3M | -$7M |
| Q4 2025 | -$23.1M | +$1M |
| Q3 2025 | -$53.9M | -$30.6M |
| Q2 2025 | -$35.3M | -$13.5M |
| Q1 2025 | -$31.3M | -$718K |
| Q4 2024 | -$24.1M | +$2K |
VOR has burned cash in almost every quarter: −$120M over the past year, against −$145M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over VOR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
VOR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.9% | +5.4M shares |
| 1 year | +853% | +53.4M shares |
| 3 years | +1701% | +56.4M shares |
| 5 years | +5260% | +58.6M shares |
| Available history | +9675% | +59.1M shares |
VOR has 60M diluted shares, up 853% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
VOR Net Leverage
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
VOR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.2 | Neutral |
| Stochastic | 24.8 | Neutral |
VOR's weekly RSI is 50 (neutral) and its Stochastic is 25 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
VOR PE vs Healthcare Sector
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over VOR on trend strength, trading above more of its moving averages.
VOR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.0 | 1.5% above |
| 20 week MA | $20.6 | 6.2% below |
| 50 week MA | $16.7 | 15% above |
| 100 week MA | $20.3 | 4.6% below |
| 200 week MA | $35.1 | 45% below |
VOR's trend is mixed: it's above two of its five weekly moving averages, and 45% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over VOR on returns for 2026, with the stronger performance.
VOR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $750.0 | $263.2 | -65% |
| 2022 | $263.2 | $140.2 | -47% |
| 2023 | $140.2 | $45.0 | -68% |
| 2024 | $45.0 | $25.4 | -44% |
| 2025 | $25.4 | $14.7 | -42% |
| 2026 YTD | $14.7 | $19.3 | +31% |
VOR has finished every year since 2021 lower, and it's up 31% so far in 2026.